ImmunityBio, Inc.

ImmunityBio, Inc. is a biotechnology company focused on developing next-generation immunotherapies that activate the patient's immune system to provide durable protection against cancer and infectious diseases. Its platforms include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's lead product is Anktiva, an FDA-approved immunotherapy used in combination with bacillus Calmette-Guérin (BCG) for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Additionally, ImmunityBio is developing 3M-052, a synthetic TLR7/8 agonist, and related formulations. The company also has collaboration agreements with the National Cancer Institute and license agreements with 3M Innovative Properties Company and Access to Advanced Health Institute.

ImmunityBio, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol IBRX. Its shares trade in United States Dollars (USD). The company is headquartered in San Diego, California, and operates primarily in the United States.

ImmunityBio operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing therapies that harness the immune system to fight diseases, particularly cancer and infectious diseases. Its work involves biologic products and product candidates, including immunotherapies and vaccines.

ImmunityBio, Inc. is based in San Diego, California, United States. While its primary operations are in the U.S., the company has collaboration agreements with entities such as the National Cancer Institute, Serum Institute of India Private Limited, and BeOne Medicines Ltd., indicating a global reach in its partnerships. Its portfolio includes license agreements with 3M Innovative Properties Company and Access to Advanced Health Institute, supporting its development of immunotherapies for cancer and infectious diseases.

ImmunityBio's lead product is Anktiva, an FDA-approved immunotherapy for bladder cancer. The company is also developing 3M-052, a synthetic TLR7/8 agonist, and related formulations. Its platforms include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. Key partnerships include collaboration agreements with the National Cancer Institute, Serum Institute of India Private Limited, and BeOne Medicines Ltd. Additionally, ImmunityBio has license agreements with 3M Innovative Properties Company and Access to Advanced Health Institute, which support its research and development efforts in immunotherapy.